Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management

ISM9528Positive

AI Analysis

Summary

Insilico Medicine has nominated ISM9528, an AI-driven, brain-penetrant, non-opioid candidate targeting a novel mechanism for pain management, following preclinical studies demonstrating a superior therapeutic profile.

Outcome Details

Nomination for development of AI-driven novel compound targeting pain management

Importance:3/10

Sentiment:

0.60

AI-driven discoverypain managementnon-opioidfirst-in-classbrain-penetrantpreclinicalPandaOmics

Related Companies

$SHWZ $BNN.DE $TRAX

Read the original article

Published by PR Newswire Biotech on July 22, 2026 1:00 PM

Read Original